These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 20833283)

  • 1. Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?
    Vergote I; Amant F; Leunen K
    Gynecol Oncol; 2010 Oct; 119(1):1-2. PubMed ID: 20833283
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists.
    Dewdney SB; Rimel BJ; Reinhart AJ; Kizer NT; Brooks RA; Massad LS; Zighelboim I
    Gynecol Oncol; 2010 Oct; 119(1):18-21. PubMed ID: 20673970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy administration for ovarian cancer by gynecologic oncologists and medical oncologists.
    Berchuck A
    J Clin Oncol; 2007 Aug; 25(23):3552; author reply 3557-8. PubMed ID: 17687164
    [No Abstract]   [Full Text] [Related]  

  • 4. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?
    Eisenkop SM; Spirtos NM
    Gynecol Oncol; 2001 Sep; 82(3):489-97. PubMed ID: 11520145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the easier way ever the better way?
    Chi DS; Bristow RE; Armstrong DK; Karlan BY
    J Clin Oncol; 2011 Nov; 29(31):4073-5. PubMed ID: 21931018
    [No Abstract]   [Full Text] [Related]  

  • 6. Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?
    Markman M
    J Clin Oncol; 2007 Aug; 25(23):3554; author reply 3557-8. PubMed ID: 17687167
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
    Chan JK; Kapp DS; Shin JY; Husain A; Teng NN; Berek JS; Osann K; Leiserowitz GS; Cress RD; O'Malley C
    Obstet Gynecol; 2007 Jun; 109(6):1342-50. PubMed ID: 17540806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LTE-commenting on "Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer" (90: 163-9).
    Eisenkop SM
    Gynecol Oncol; 2004 Mar; 92(3):1017-8; author reply 1018-9. PubMed ID: 14984983
    [No Abstract]   [Full Text] [Related]  

  • 9. Oncologist preferences for health states associated with the treatment of advanced ovarian cancer.
    Hess LM; Malone DC; Skrepnek GH; Reed PG; Armstrong E; Coons SJ
    Appl Health Econ Health Policy; 2010; 8(4):217-23. PubMed ID: 20578777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type of oncology specialist and treatment-related outcomes in ovarian cancer.
    Hoffman MA; Iqbal U
    J Clin Oncol; 2007 Aug; 25(23):3553; author reply 3557-8. PubMed ID: 17687165
    [No Abstract]   [Full Text] [Related]  

  • 11. Ovarian cancer and the battle of the specialists.
    McGuire WP
    J Clin Oncol; 2007 Aug; 25(23):3554-5; author reply 3557-8. PubMed ID: 17687166
    [No Abstract]   [Full Text] [Related]  

  • 12. [Gynecologic oncologists and their practice in the U.S.A].
    Tsukamoto N
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):69-75. PubMed ID: 9987500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians.
    Calhoun EA; Fishman DA; Lurain JR; Welshman EE; Bennett CL
    Gynecol Oncol; 2004 Apr; 93(1):164-9. PubMed ID: 15047231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
    Carter J; Durfee J
    Gynecol Oncol; 2007 Dec; 107(3):586-9. PubMed ID: 17949798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer.
    Chi DS; Schwartz PE
    Gynecol Oncol; 2008 Dec; 111(3):391-9. PubMed ID: 19041036
    [No Abstract]   [Full Text] [Related]  

  • 16. More than a name.
    Blank SV; Curtin JP
    J Clin Oncol; 2007 Aug; 25(23):3551; author reply 3557-8. PubMed ID: 17687163
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer.
    Krzyzanowska MK; Regan MM; Powell M; Earle CC; Weeks JC
    J Am Coll Surg; 2009 Feb; 208(2):202-9. PubMed ID: 19228531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neoadjuvant chemotherapy in the treatment of ovarian cancer].
    Lehoczky O
    Orv Hetil; 2005 Sep; 146(38):1951-5. PubMed ID: 16238247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.
    Ansquer Y; Leblanc E; Clough K; Morice P; Dauplat J; Mathevet P; Lhommé C; Scherer C; Tigaud JD; Benchaib M; Fourme E; Castaigne D; Querleu D; Dargent D
    Cancer; 2001 Jun; 91(12):2329-34. PubMed ID: 11413522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced cytoreductive surgery in gynecologic oncology.
    Bristow RE
    Gynecol Oncol; 2009 Aug; 114(2 Suppl):S1-2. PubMed ID: 19573698
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.